Aberystwyth University

Characterization of two in vivo-expressesd methyltransferases of the Mycobacterium tuberculosis complex

Golby, Paul; Nunez, Javier; Cockle, Paul J.; Ewer, Katie; Logan, Karen; Hogarth, Philip; Vordermeier, H. Martin; Hinds, Jason; Hewinson, R. Glyn; Gordon, Stephen V.

Characterization of two *in vivo*-expressed methyltransferases of the *Mycobacterium tuberculosis* complex: antigenicity and genetic regulation

Paul Golby,[1] Javier Nunez,[1] Paul J. Cockle,[1] Katie Ewer,[1] Karen Logan,[1]† Philip Hogarth,[1] H. Martin Vordermeier,[1] Jason Hinds,[2] R. Glyn Hewinson[1] and Stephen V. Gordon[1]‡

[1]Veterinary Laboratories Agency (Weybridge), New Haw, Addlestone, Surrey KT15 3NB, UK.

[2]Bacterial Microarray Group, Department of Cellular and Molecular Medicine, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK

Correspondence
Stephen V. Gordon
stephen.gordon@ucd.ie

Genome sequencing of *Mycobacterium tuberculosis* complex members has accelerated the search for new disease-control tools. Antigen mining is one area that has benefited enormously from access to genome data. As part of an ongoing antigen mining programme, we screened genes that were previously identified by transcriptome analysis as upregulated in response to an *in vitro* acid shock for their *in vivo* expression profile and antigenicity. We show that the genes encoding two methyltransferases, *Mb1438c/Rv1403c* and *Mb1440c/Rv1404c*, were highly upregulated in a mouse model of infection, and were antigenic in *M. bovis*-infected cattle. As the genes encoding these antigens were highly upregulated *in vivo*, we sought to define their genetic regulation. A mutant was constructed that was deleted for their putative regulator, *Mb1439/Rv1404*; loss of the regulator led to increased expression of the flanking methyltransferases and a defined set of distal genes. This work has therefore generated both applied and fundamental outputs, with the description of novel mycobacterial antigens that can now be moved into field trials, but also with the description of a regulatory network that is responsive to both *in vivo* and *in vitro* stimuli.

INTRODUCTION

Mycobacterium bovis is the causative agent of bovine tuberculosis, a disease responsible for annual losses to global agriculture of \$3 billion and with serious repercussions for public health and animal welfare. Control of bovine tuberculosis in many countries involves regular testing of cattle (skin test) with a crude preparation of mycobacterial antigens termed PPD (purified protein derivative, also known as tuberculin), followed by

compulsory slaughter of positive reactors. Vaccination is not used as part of the control strategy since the only available vaccine, the human tuberculosis vaccine bacille Calmette–Guérin (BCG), imparts only limited protection in cattle and compromises the use of the skin test. In order to control bovine tuberculosis there is therefore an acute need to develop both improved vaccines and diagnostic tests.

Antigens have already been identified that are feeding into the design of new control strategies. The potent T-cell antigens ESAT-6 and CFP-10 were originally identified from *Mycobacterium tuberculosis* culture filtrates (Sørensen *et al.*, 1995; Skjøt *et al.*, 2000), with the genes encoding these antigens deleted from the genome of the BCG vaccine strain (Mahairas *et al.*, 1996). They therefore have obvious application to the differential diagnosis of vaccination versus infection. Similarly, antigens have been described that impart significant levels of protection against challenge when used as subunit vaccines (Ibanga *et al.*, 2006; Orme, 2006; Vordermeier *et al.*, 2006). However, we need to expand our repertoire of known antigens to ensure that the best candidates, or cocktails, are optimized and applied.

One approach to the discovery of new antigens is to exploit the information contained in the *M. bovis* genome. Sequencing the *M. bovis* genome revealed ~4000 protein-encoding genes (Garnier *et al.*, 2003); however, it is not feasible to screen all of these proteins for diagnostic or vaccine potential. Instead a biologically relevant filter must be used to sift the genome information to a manageable subset. One subset of obvious interest would be genes that are upregulated *in vivo*, but there are difficulties in identifying global expression changes of *M. bovis* in cattle. A parallel approach would be to identify genes that respond *in vitro* to a surrogate of the *in vivo* milieu, such as nutrient starvation, hypoxia or acid shock, and then to screen the identified genes for their expression profile responses *in vivo* using targeted methods. Following this approach we chose acid as our *in vitro* surrogate and in doing so found 60 *M. bovis* genes that were upregulated when the bacteria were exposed to acid shock (Golby *et al.*, 2007).

In this study, we have determined whether *in vitro* acid-induced genes are also upregulated *in vivo*, and then screened the resulting candidates for their immunogenicity in *M. bovis*-infected cattle. Using this approach, we have identified two putative methyltransferase-encoding genes which are highly upregulated *in vivo* and whose products are immunogenic in cattle. We furthermore identified the regulator of these methyltransferase genes as a route to understanding their upregulation *in vivo*.

METHODS

Bacterial strains and growth conditions; gene designations. *M. bovis* 2122/97 (Garnier *et al.*, 2003) was routinely grown in Middlebrook 7H9 broth supplemented with 10 % albumin-dextrose-catalase (ADC, Difco), 0.05 % Tween and 10 mM pyruvate, or on 7H11 agar supplemented with 10 % oleic acid-albumin-dextrose-catalase (OADC, Difco), and 10 mM pyruvate. Similar media were used for the growth of *M. tuberculosis* H37Rv, except the pyruvate was replaced with 0.2 % or 0.5 % glycerol for growth in liquid or on solid media, respectively. Liquid cultures were grown at 37 °C in 2 l bottles rotated at 2–3 r.p.m. Where used, hygromycin and kanamycin were present at 150 μg ml^{-1} and 50 μg ml^{-1}, respectively. For gene designations, 'Mb' denotes a gene from *M. bovis* 2122, while 'Rv' is a gene from *M. tuberculosis* H37Rv (Cole *et al.*, 1998; Garnier *et al.*, 2003).

Extraction of RNA from mouse tissues and broth cultures. Female BALB/c mice were intranasally infected with 200–300 c.f.u. of *M. bovis* and euthanized when clinical signs of tuberculosis disease became apparent. Lungs were removed from the mice, and for each lung one half was placed in a vial containing 10 ml Trizol and the other half in 10 ml phosphate-buffered saline solution (PBS) plus 0.05 % Triton X-100; then both vials were stored at –80 °C. When required, the vials were thawed and the contents homogenized. The Trizol-lung homogenate was transferred to Ribolyser tubes and RNA extracted according to the protocol outlined by Bacon *et al.* (2004). The PBS-lung homogenate was serially diluted and plated onto solid growth medium. The plates were incubated at 37 °C for 3–4 weeks before the numbers of *M. bovis* colonies were counted. Viable counts were approximately 10^8–10^9 c.f.u. per lung.

RNA was prepared from broth cultures of *M. tuberculosis* and *M. bovis* using the guanidinium thiocyanate procedure (Bacon *et al.*, 2004). Quantitative real-time PCR (qRT-PCR) experiments were performed as described by Golby *et al.* (2007); the sequences of the primer pairs are given in Supplementary Table S1, available with the online version of this paper.

Antigen discovery. A set of 469 peptides spanning the lengths of 11 open reading frames were purchased from Mimitopes. The peptides were 20 residues in length, each with a 12 residue overlap with its neighbouring peptide. Peptides were formulated into pools of approximately 8–12 peptides. The gamma-interferon (IFN-γ) immunoassay methodology was as described previously (Cockle *et al.*, 2002). For screening purposes, bloods were taken from 21 reactor cattle naturally infected with *M. bovis*. The IFN-γ concentration was determined using the BOVIGAM ELISA kit (Prionics). An antigen was defined as giving a positive response when the A_{450} with antigen minus A_{450} without antigens was ⩾0.1. Absorbance readings were converted to concentration of IFN-γ (pg ml^{-1}) using the following equation: $(A_{450} \times 30.9) + 0.5658$.

Construction of *M. tuberculosis* H37Rv *Rv1403c–Rv1405c* deletion strain PG100. A 0.9 kb fragment containing the 5′ ends of the *Mb1440c* and *fmt* genes was PCR amplified using *M. bovis* 2122 chromosomal DNA and primers Mb1440c5′F1 and Mb1440c5′R. (Sequences of primers used in the construction of plasmids and the verification of the mutant are given in Supplementary Table S2.) The PCR product was digested with *Bam*HI and cloned into the ColE1 plasmid pSMT100, which contains a *hyg*R cassette and the *sacB* gene, to give the construct pPG28. A 0.9 kb fragment containing the 3′ ends of *Rv1403c* and *priA* was PCR amplified using primers Mb1438c3′F and Mb1438c3′R1, digested with *Xba*I and *Pst*I and cloned into pPG28 to give pPG34 (Fig. 1). The plasmid was used to transform *M. tuberculosis* H37Rv and transformants were plated onto 7H11 medium containing 0.5 % glycerol, OADC, 2 % sucrose and hygromycin. Hygromycin- and sucrose-resistant colonies were screened for loss of the *Rv1403c–Rv1405c* genes by PCR using primers that anneal to the 5′ end of *Rv1405c* and the 3′ end of *Rv1403c*. Putative ΔRv1403c–Rv1405c mutants were verified by PCR using primers that anneal to internal sequences of the hygromycin-resistance cassette and the *fmt* gene, hygF and fmtR1 respectively.

Construction of *Rv1405c*-, *Rv1404*- and *Rv1403c*-overexpressing plasmids. The *Rv1405c*-overexpressing plasmid was prepared by PCR amplification of a 1.4 kb fragment encompassing *Rv1405c* and 525 bp upstream of the initiation codon (fragment A, Fig. 1) using *M. tuberculosis* H37Rv genomic DNA as a template and primers Rv1405cF1 and Rv1405cR1. The PCR product was digested with *Bam*HI and cloned into *Bam*HI-cut pMD31 (Donnelly-Wu *et al.*, 1993) to give plasmid pPG53 (Fig. 1). The *Rv1403c*-overexpressing plasmid was constructed by amplifying a 1.5 kb fragment encompassing *Rv1403c* and 515 bp upstream of its start codon (fragment B, Fig. 1) using primers Rv1403cF1 and Rv1403cR1. The product was digested with *Bam*HI and cloned into *Bam*HI-cut pMD31 to give plasmid pPG54. The construct overexpressing both *Rv1405c* and *Rv1404* was prepared by amplification of a 1 kb fragment containing *Rv1404* and 456 bp upstream of the start codon (fragment C, Fig. 1) using primers Rv1404F1 and Rv1404R1. The PCR product was digested with *Xba*I and *Hin*dIII and cloned into the corresponding sites of plasmid pPG53 to give construct pPG55. Similarly, the *Rv1403c*- and *Rv1404*-containing plasmid was created by cloning the 1 kb *Rv1404*-containing PCR fragment previously described into plasmid pPG54 to create the construct pPG56. To construct the *Rv1404*-overexpressing plasmid used in the microarray experiments the 1 kb *Xba*I–*Hin*dIII *Rv1404*-containing fragment of pPG55 was cloned into the corresponding sites of pMD31 to generate the construct pPG57. Plasmid pPG72, which contains a 3 kb '*priA*-*Rv1403c*-*Rv1404*-*Rv1405c*-*fmt*' fragment, was

Fig. 1. Schematic representation of the *Rv1405c–Rv1403c* genomic region. The direction of the arrows indicates the relative direction of transcription for each gene. Restriction enzyme sites incorporated into the sequences of the PCR primers/products are: H, *Hind*III; B, *Bam*HI; X, *Xba*I; A, *Afe*I.

constructed in several steps. Firstly, a 1.6 kb ′*priA-Rv1403c-Rv1404-Rv1405c*′-containing fragment (fragment D, Fig. 1) was PCR amplified using primers priAF and Rv1405cR3, and then a 1.4 kb ′*Rv1405c-fmt*′-containing fragment (fragment E, Fig. 1) was amplified using primers Rv1405cF2 and fmtR2. The two PCR fragments were digested with *Hind*III and *Afe*I, and cloned into *Hind*III-cut pMD31 to yield pPG72. Sequences of primers used in plasmid construction are given in Supplementary Table S2.

Microarray analysis. Three independent experiments (biological replicates) were carried out. For each strain in each experiment, two microarrays (technical replicates) were performed, with each micro-array having two measurements of every gene. Two colour hybridizations were performed using whole-genome *M. bovis/M. tuberculosis* microarrays; the array design is available in BμG@Sbase, accession no. A-BUGS-31 (http://bugs.sgul.ac.uk/A-BUGS-31) and also ArrayExpress, accession no. A-BUGS-31. Cy5 and Cy3 fluorescently labelled probes synthesized from RNA and genomic DNA, respectively, were hybridized to microarrays. Further details concerning the design of the microarrays and procedures used for probe manufacture and hybridization can be found in Golby *et al.* (2007).

Scanning and image analysis. Microarrays were scanned using a GenePix 4000A microarray scanner (Axon Instruments) with the photomultiplier tube set in the range 550–750 V, so that spots with the highest signal intensities were just below the level of saturation. Fluorescent spots on each image were quantified using BlueFuse for Microarrays software (BlueGnome).

Microarray data analysis. Data from every microarray were normalized by calculating the log ratio of the Cy5 to Cy3 signal for every spot, and then dividing each log ratio by the median of the log ratios of all spots (excluding control spots) on the array. As an additional normalization step, a median absolute deviation (MAD) scale transformation was applied to the normalized data from the previous step. For each microarray, duplicate spots were averaged, and then the average expression of every gene across all technical replicate microarrays was calculated. Averages of the three biological replicates were used to compare gene expression between strains. For each gene, a moderate *t*-test was applied and those genes with a *P*-value less than 0.05 were selected. From this gene list, those genes whose average expression differed by more than 3-fold between strains were selected. Fully annotated microarray data have been deposited in BμG@Sbase (accession number: E-BUGS-59; http://bugs.sgul.ac.uk/E-BUGS-59) and also ArrayExpress (accession number: E-BUGS-59).

RESULTS

Analysis of *in vivo* gene expression by qRT-PCR

We previously described the effect of acid shock on the transcriptome of *M. bovis* and *M. tuberculosis* grown in a chemostat (Golby *et al.*, 2007), and identified *Mb1438c* and *Mb1440c* (and the *M. tuberculosis* orthologues *Rv1403c* and *Rv1405c*, respectively) as two of the genes most highly induced in response to acid shock. Both genes were induced within 5 min of acid shock, and maintained high expression over 24 h (Golby *et al.*, 2007). However, the

question was whether this *in vitro* stress truly paralleled stresses experienced by *M. bovis* and *M. tuberculosis in vivo*. To determine whether *in vitro* acid-induced genes were also upregulated *in vivo* we screened 26 acid-shock-induced genes, selected on the basis of putative function and fold change, by qRT-PCR to determine their gene expression *in vivo* relative to an *in vitro* control (Table 1). The genes *Rv1403c/Mb1438c*, *Rv1404/Mb1439*, *Rv1405/Mb1440c* and 11 of the other 26 genes were upregulated *in vivo*, with *Rv1405c/Mb1440c* and *Rv1403c/Mb1438c* showing changes in expression of 326- and 37-fold, respectively, *in vivo* compared to *in vitro* (Table 1). The standard deviations for each gene were high, reflecting the variability in gene expression observed across different mice, but generally the fold increases in expression were in agreement with previous data on upregulation after acid shock (Golby *et al.*, 2007).

Antigen screening

We next determined whether *in vivo*-induced genes were antigenic in the bovine host. We selected 11 of the *in vivo*-upregulated genes, including the highly upregulated *Rv1403c/Mb1438c* and *Rv1405c/Mb1440c* as well as their

Table 2. Gene products screened for antigenicity

M. bovis CDS	*M. tuberculosis* CDS	Gene name	Product size (aa)	Peptide pools
Mb1438c	*Rv1403c*		274	1–3
Mb1439	*Rv1404*		160	4–5
Mb1440c	*Rv1405c*		274	6–8
Mb0217	*Rv0211*	*pckA*	606	9–15
Mb0476	*Rv0467*	*icl*	428	16–20
Mb1788	*Rv1758*	*cut1*	218	21–23
Mb1217c	*Rv1185c*	*fadD21*	578	24–30
Mb3163	*Rv3139*	*fadE24*	468	31–36
Mb2454	*Rv2428*	*ahpC*	195	37–38
Mb1086	*Rv1057*		393	39–43
Mb1495	*Rv1460*		268	44–46

putative regulator, *Rv1404/Mb1439*. Immunogenicity was assessed using an IFN-γ immunoassay using blood obtained from cattle naturally infected with *M. bovis*. Peptides derived from the sequences of the 11 CDS were synthesized and pooled into 46 groups, with each group consisting of 8–12 overlapping peptides (Table 2). Whole-blood cultures in the presence of the peptide pools were established and IFN-γ production measured after 48 h of culture. Fig. 2 shows the percentage of cattle tested that

Table 1. *In vivo* expression of acid-shock-induced genes

M. bovis CDS	*M. tuberculosis* CDS	Gene	Fold change*
Mb0217	*Rv0211*	*pckA*	25.5 ± 10
Mb0476	*Rv0467*	*icl*	18 ± 19.2
Mb0529c	*Rv0516c*		NC
Mb1058	*Rv1029*	*kdpA*	NC
Mb1086	*Rv1057*		8.4 ± 4.7
Mb1162	*Rv1131*	*gltA1*	NC
Mb1214	*Rv1182*	*papA3*	NC
Mb1216c	*Rv1184c*		7.3 ± 2.8
Mb1217c	*Rv1185c*	*fadD21*	4.8 ± 2.4
Mb1438c	*Rv1403c*		36.5 ± 16
Mb1439	*Rv1404*		3.9 ± 1.9
Mb1440c	*Rv1405c*		325.9 ± 138.7
Mb1495	*Rv1460*		3.3 ± 1.5
Mb1618c	*Rv1592c*		1.6 ± 0.8
Mb1709	*Rv1682*		NC
Mb1788	*Rv1758*	*cut1*	2.7 ± 1.1
Mb1803	*Rv1774*		NC
Mb2057c	*Rv2031c*	*hspX*	38.7 ± 19.7
Mb2194c	*Rv2172c*		NC
Mb2364	*Rv2336*		NC
Mb2454	*Rv2428*	*ahpC*	4.1 ± 1.9
Mb2587	*Rv2557*		NC
Mb2955	*Rv2930*	*fadD26*	NC
Mb3028c	*Rv3003c*	*ilvB1*	NC
Mb3116	*Rv3089*	*fadD13*	NC
Mb3163	*Rv3139*	*fadE24*	4.7 ± 2.0

*Fold changes are the mean ratios ± SD of expression measured in mouse lung tissues compared with expression measured of *in vitro*-grown *M. bovis*. NC, No change.

Fig. 2. Percentage of cattle that responded positively to antigens tested. The dashed vertical line indicates the positive cutoff value of 40 %. PPDA is purified protein derivative from *M. avium*, PPDB is purified protein derivative from *M. tuberculosis*, and SEB is staphylococcal enterotoxin B. Peptide pools giving positive responses are pool 1 (Mb1438c/Rv1403c), pools 6 and 8 (Mb1440c/Rv1405c), pool 25 (FadD21) and pool 32 (FadE24).

gave a positive response for each of the peptide pools tested. All cattle showed a positive response to PPD from *M. avium* (PPDA) and *M. bovis* (PPDB), as well as a staphylococccal enterotoxin B control. Five of the peptide pools tested showed a positive response in at least 40 % of cattle tested, namely pools 1 (containing peptides from Mb1438c), 6 and 8 (Mb1440c), 25 (FadD21) and 32 (FadE24), with Mb1438c being the strongest inducer of IFN-γ (Fig. 3). For diagnostic use, secreted antigens are of particular interest as host responsiveness is indicative of ongoing infection with viable bacilli. Furthermore, early and sustained upregulation of genes *Mb1440c* and *Mb1438c* *in vivo* points to their potential as subunit vaccines, as responses seen early in infection may be associated with protection.

Isolation of a Δ*Rv1403c–Rv1405c* :: *hyg* mutant

The high degree of upregulation of the two putative methyltransferase-encoding genes *Mb1440c* and *Mb1438c* and the immunogenic properties of the corresponding proteins prompted us to examine their regulation. *Rv1404/ Mb1439* encodes a protein that has some homology to the MarR family of transcriptional regulators, and we have previously speculated that it could function to regulate the expression of *Rv1403c*/*Mb1438c* and *Rv1405c*/*Mb1440c* (Golby *et al.*, 2007). In order to test this, we sought to construct an *Rv1404/Mb1439* deletion mutant. Attempts to isolate a targeted deletion of *Rv1404* using plasmid- or bacteriophage-based mutagenesis systems proved unsuccessful in *M. bovis*. We were, however, successful in isolating a triple mutant of *M. tuberculosis* H37Rv in which

the genes *Rv1403c*, *Rv1404* and *Rv1405c* were deleted and replaced with a hygromycin-resistance cassette. The resulting strain was designated PG100. Allelic exchange of *Rv1403c-Rv1405c* with the *hygR* resistance cassette in PG100 was confirmed by PCR using primers that anneal to the hygromycin-resistance cassette and the adjacent *fmt* gene (Fig. 1).

Liquid culture growth experiments using PG100 showed that it grew more slowly, and had a much greater tendency to aggregate, than the wild-type (Fig. 4). The defective growth phenotype of the mutant could only be partially corrected by transformation with a plasmid (pPG72) that contained the genes *Rv1405c*, *Rv1404* and *Rv1403c*. Transformation of the mutant with a plasmid over-expressing *Rv1404* alone (pPG57) conferred a similar level of complementation to that seen with pPG72 (Fig. 4). Complementation with *Rv1404* had a similar effect to addition of all three deleted genes, suggesting that the PG100 growth defect was due to the loss of *Rv1404* and not *Rv1405c* or *Rv1403c*. However, failure to achieve full *trans* complementation using the *Rv1404* overexpression construct suggests a complex regulatory circuit that may require *cis* complementation.

Rv1404 is a transcriptional repressor of *Rv1405c* and *Rv1403c*

qRT-PCR was used to study the effect of Rv1404 on the expression of *Rv1405c* and *Rv1403c* in *M. tuberculosis*.

Fig. 3. IFN-γ responses induced to antigens in *M. bovis*-infected cattle. The results of those cattle that gave only a positive response are shown. Horizontal lines indicate the mean IFN-γ response for a particular antigen pool. An antigen is defined as giving a positive response when the A_{450} with antigen minus A_{450} without antigen was ≥0.1. The peptides are contained within Mb1438c/Rv1403c (pool 1), Mb1440c/Rv1405c (pools 6 and 8), FadD21 (pool 25) and FadE24 (pool 32).

Fig. 4. Growth phenotype of the *M. tuberculosis* PG100 triple mutant. The growth of the *M. tuberculosis* H37Rv wild-type plus pMD31 empty vector (■), PG100 mutant with pMD31 vector (▲), and complemented mutants (▼, ●) is shown. Complementation of PG100 with plasmid pPG72 (▼), which contained the *Rv1403c-Rv1404-Rv1405c* genes deleted from PG100, or with pPG57 (●), containing just the *Rv1404* regulator, failed to restore the growth of the mutant to wild-type levels. Data shown are from one experiment, representative of three.

Several plasmid constructs consisting of DNA fragments containing native operator-promoter and coding sequences of *Rv1405c*, *Rv1404* and *Rv1403c* cloned into the multicopy plasmid pMD31 were constructed (see Methods and Fig. 1) and introduced into PG100. The level of expression of *Rv1405c* was found to be over 700-fold higher in PG100 carrying the *Rv1405c* construct pPG53 than the wild-type strain (Table 3), suggesting that the product of *Rv1404*, absent in the mutant, represses the transcription of *Rv1405c*. Based on the assumption that there are 5–10 copies of pMD31 per cell in mycobacteria (Donnelly-Wu *et al.*, 1993), one can estimate that the expression of *Rv1405c* in a Δ*Rv1404* background is approximately 70–150-fold higher than in the wild-type. Evidence to support the proposed repressor role of Rv1404 on the expression of *Rv1405c* was provided by the finding that the expression of *Rv1405c* in PG100 carrying the plasmid pPG55, which contains both *Rv1405c* and *Rv1404*, is 45-fold less than the mutant carrying pPG53. Expression of *Rv1403c* was also found to be 37.7-fold higher in PG100 carrying the *Rv1403c*-containing pPG54 compared to the wild-type, but only 3.4-fold higher in PG100 carrying both *Rv1403c* and *Rv1404* (pPG56). This suggests that Rv1404 represses the transcription of both *Rv1405c* and *Rv1403c*, but the lower fold induction levels of *Rv1403c* in the mutant would suggest that the promoter of *Rv1403c* is weaker than that of *Rv1405c*.

Transcriptome analysis of PG100

The growth defect of the PG100 Δ*Rv1405c*–*Rv1403c* triple mutant could be partially reversed by complementing with the Rv1404 regulator, suggesting that Rv1404 regulated genes in addition to *Rv1405c* and *Rv1403c*, genes that may include the methylation target of Rv1403c and Rv1405c. In order to identify these genes, DNA microarrays were used to compare the transcriptional profiles of the wild-type H37Rv and PG100. Table 4 shows the fold changes in expression for 28 genes that showed a minimum 3-fold differential expression in PG100 compared with H37Rv. Introduction of a plasmid overexpressing *Rv1404*, pPG57, into the mutant strain reduced the expression of 25 of the 28 differentially expressed genes to levels that were similar (<2-fold difference) to those seen in the wild-type.

Table 3. Effect of *Rv1404* on the expression of *Rv1405c* and *Rv1403c* measured by real-time qRT-PCR

Gene expression values are relative to those in the wild-type.

Plasmid in PG100	*Rv1405c*	*Rv1404*	*Rv1403c*
pPG53	739.0	ND	ND
pPG54	ND	9.0	37.7
pPG55	16.4	7.8	ND
pPG56	ND	10.0	3.4

ND, Not detected.

Twenty-two of the 25 *Rv1404*-regulated genes were upregulated in PG100, suggesting that Rv1404 is predominantly a transcriptional repressor.

Six of the twenty-seven genes identified as showing a 3-fold or greater difference in expression between the wild-type and the mutant were selected, based on putative function and fold change, for analysis by qRT-PCR. Fig. 5 shows that the fold changes in expression measured by microarray and qRT-PCR for these six genes are comparable, validating the results of the microarray analysis.

DISCUSSION

There is a critical need for new tools for the control of both *M. bovis* and *M. tuberculosis* infection and disease. We have used a combination of global gene expression studies and antigen mining to identify novel antigens of *M. bovis*. We have also moved this applied research back to a more fundamental setting, identifying the regulatory network that controls the expression of the two most promising antigens we identified. We believe that this combination of applied and fundamental research offers the best chance to accelerate the generation of new control tools.

Two of the most highly upregulated genes in response to *in vitro* acid shock, the methyltransferase-encoding genes *Rv1403c*/*Mb1438c* and *Rv1405c*/*Mb1440c*, were also found to be highly upregulated *in vivo*. The expression of *Mb1440c in vivo* was particularly high, showing an approximately 350-fold higher level of expression compared to an *in vitro* control. This level of induction is comparable to the 70–150-fold induction of *Rv1405c* seen in an Δ*Rv1404* mutant background compared to the wild-type, suggesting that *Rv1405c*/*Mb1440c* expression was completely derepressed in infected mouse lung tissues.

Expression of *Mb1440c*/*Rv1405c* and *Mb1438c*/*Rv1403c* was shown to be tightly regulated by the product of the *Mb1439*/*Rv1404* gene, encoding a member of the MarR family of transcriptional regulators (Ellison & Miller, 2006; Grkovic *et al.*, 2002). *Mb1440c*/*Rv1405c* and *Mb1438c*/*Rv1403c* showed very low expression under *in vitro* non-stressed and *ex vivo* conditions, but high expression under *in vivo* and stressed *in vitro* conditions. It is noteworthy that in *Mycobacterium ulcerans* a transposon is inserted in the promoter/operator region of the *Mb1439*/*Rv1404* orthologue (Stinear *et al.*, 2007), presumably resulting in constitutive expression of the *Rv1405c* orthologue since its protein product was detected in the cytoplasmic fraction of *M. ulcerans* by LC-MS (annotated at http://genolist.pasteur.fr/BuruList/).

The majority of MarR regulators act as repressors, and their activity can be modulated through binding of an inducer molecule to the MarR regulator (Ellison & Miller, 2006; Grkovic *et al.*, 2002). Genes regulated by MarR family members are repressed in the absence of the inducer and derepressed in the presence of inducer. Many MarR

Table 4. Gene expression control by Rv1404

Rv no.	Gene	Product	Fold change*	
			Wild-type vs PG100	Wild-type vs PG100(pPG57)
Rv0193c		Hypothetical protein	30.1	NC
Rv0194		ABC transporter	13.1	NC
Rv0195		Transcriptional regulator	52.7	NC
Rv0341	*iniB*	Isoniazid-inducible gene	4.0	4.0
Rv0575c†		Possible oxidoreductase	6.0	NC
Rv1376		Conserved hypothetical protein	7.7	NC
Rv1392†	*metK*	AdoMet synthase	4.1	NC
Rv1402	*priA*	Putative primosomal protein	6.3	NC
Rv1592c		Conserved hypothetical protein	4.0	4.4
Rv1620c	*cydC*	Cytochrome transporter assembly protein	0.31	NC
Rv1623c	*cydA*	Cytochrome transporter assembly protein	0.30	NC
Rv1682†		Coiled-coil protein	10.9	NC
Rv1809†	*PPE33*	PPE family protein	3.0	NC
Rv2281	*pitB1*	Phosphate transporter	3.5	NC
Rv2322c†	*rocD1*	Ornithine aminotransferase	3.6	NC
Rv2389c†	*rpfD*	Resuscitation factor	5.8	NC
Rv2390c†		Conserved hypothetical protein	8.6	NC
Rv2700		Possible secreted protein	4.4	NC
Rv2817c		Conserved hypothetical protein	0.32	NC
Rv2930	*fadD26*	Fatty acid synthase	3.7	NC
Rv2934	*ppsD*	Polyketide synthase	3.9	4.7
Rv3137		Probable monophosphatase	3.1	NC
Rv3289c		Possible transmembrane protein	3.1	NC
Rv3371†		Conserved hypothetical protein	4.1	NC
Rv3531c		Hypothetical protein	3.2	NC
Rv3532†	*PPE61*	PPE family protein	10.2	NC
Rv3533c	*PPE62*	PPE family protein	3.3	NC
Rv3746c†	*PE34*	PE family protein	3.9	NC

*NC, No change.

†Genes shown previously to be 3-fold or more upregulated in *M. tuberculosis* H37Rv in response to acid.

repressors are also autoregulatory, repressing their own expression in the absence of inducer. This would explain the observed moderate increase (3–4-fold) in expression of *Mb1439/Rv1404* observed under acidic and *in vivo* conditions, as the regulator would be unable to bind to its operator and repress its own expression. In addition to *Rv1405c* and *Rv1403c*, deletion of Rv1404 was also shown to affect the expression of another 25 genes, 10 of which were previously shown to be upregulated in response to acid shock in *M. tuberculosis* H37Rv. This suggests that *Rv1404/Mb1439* is an important regulator in the response of *M. tuberculosis* and *M. bovis* to acid shock. Curiously, the three genes that show the highest induction in the *Rv1404* mutant (*Rv0193c–Rv0195*) show no upregulation in response to acid (Golby *et al.*, 2007), suggesting that the expression of these genes could be regulated by other factors in addition to Rv1404.

In a seminal study, Sassetti and Rubin used a combination of saturation mutagenesis with *in vivo* selection to identify *M. tuberculosis* genes that were required for survival in a mouse infection model; *Rv1405c* was among the 197 genes identified as important for virulence (Sassetti & Rubin, 2003). Hence, methylation of Rv1405c's target is involved in virulence. There are a number of examples where methylation of mycobacterial cellular components has been implicated in the virulence of *M. tuberculosis*. Methylation of the mycobacterial heparin-binding haemagglutinin adhesin (HBHA), an extrapulmonary dissemination factor (Pethe *et al.*, 2001), is required for T-cell immunity and protects the molecule against proteolysis (Pethe *et al.*, 2002; Temmerman *et al.*, 2004). Similarly, cyclopropanation of mycolic acids by *pcaA* and *cmaA2* has been shown to be involved in virulence of *M. tuberculosis* (Glickman *et al.*, 2000; Rao *et al.*, 2006). Overexpression of *Rv1405c* in *M. smegmatis* mc²155 caused no significant changes in mycolic acid profile (data not shown), suggesting that Rv1405c is not involved in cyclopropanation of mycolic acids. Analysis of the *Rv1405c* locus reveals genes encoding formyl methionine transferase (*fmt*) and a putative rRNA methyltransferase (*fmu*), suggesting that *Rv1405c/Rv1403c* could be involved in methylating a component of the

Fig. 5. Confirmation of microarray analysis by real-time qRT-PCR. Fold changes are the mean ratios ± SEM of gene expression measured in the mutant PG100 compared with the wild-type H37Rv. Black bars represent the microarray data and white bars the qRT-PCR data

protein translational machinery; however, how this would play a role in virulence is unknown.

The Δ*Rv1403c-Rv1404-Rv1405c* mutant also showed upregulation of distal genes. *Rv0193c–Rv0195* showed the highest degree of upregulation (13–52-fold), and their contiguity suggests that their products could be functionally related. *Rv0195* encodes a response regulator of the two-component family and, like *Rv1403c* and *Rv1405c*, has been shown to be upregulated in response to low oxygen conditions (Muttucumaru *et al.*, 2004; Voskuil *et al.*, 2004). The gene *Rv0194* encodes a putative ABC-type transporter, but its function and substrate are unknown. The gene is unique amongst other ABC-type transporters of *M. tuberculosis* in having two membrane-spanning domains and two nucleotide-binding domains in a single polypeptide.

In summary, on an applied level we have defined novel *M. bovis* antigens that are now being moved forward to larger field trials. On a fundamental level, we have described the regulation of genes encoding two methyltransferases in *M. tuberculosis*, one of which, Rv1405c, has been implicated as a virulence factor. The next step will be to identify the target(s) of these methyltransferases to elucidate their role in virulence.

ACKNOWLEDGEMENTS

REFERENCES

Bacon, J., James, B. W., Wernisch, L., Williams, A., Morley, K. A., Hatch, G. J., Mangan, J. A., Hinds, J., Stoker, N. G. & other authors (2004). The influence of reduced oxygen availability on pathogenicity and gene expression in *Mycobacterium tuberculosis*. *Tuberculosis (Edinb)* **84**, 205–217.

Cockle, P. J., Gordon, S. V., Lalvani, A., Buddle, B. M., Hewinson, R. G. & Vordermeier, H. M. (2002). Identification of novel *Mycobacterium tuberculosis* antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics. *Infect Immun* **70**, 6996–7003.

Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S. & other authors (1998). Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* **393**, 537–544.

Donnelly-Wu, M. K., Jacobs, W. R., Jr & Hatfull, G. F. (1993). Superinfection immunity of mycobacteriophage L5: applications for genetic transformation of mycobacteria. *Mol Microbiol* **7**, 407–417.

Ellison, D. W. & Miller, V. L. (2006). Regulation of virulence by members of the MarR/SlyA family. *Curr Opin Microbiol* **9**, 153–159.

Garnier, T., Eiglmeier, K., Camus, J. C., Medina, N., Mansoor, H., Pryor, M., Duthoy, S., Grondin, S., Lacroix, C. & other authors (2003). The complete genome sequence of *Mycobacterium bovis*. *Proc Natl Acad Sci U S A* **100**, 7877–7882.

Glickman, M. S., Cox, J. S. & Jacobs, W. R., Jr (2000). A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of *Mycobacterium tuberculosis*. *Mol Cell* **5**, 717–727.

Golby, P., Hatch, K. A., Bacon, J., Cooney, R., Riley, P., Allnutt, J., Hinds, J., Nunez, J., Marsh, P. D. & other authors (2007). Comparative transcriptomics reveals key gene expression differences between the human and bovine pathogens of the *Mycobacterium tuberculosis* complex. *Microbiology* **153**, 3323–3336.

Grkovic, S., Brown, M. H. & Skurray, R. A. (2002). Regulation of bacterial drug export systems. *Microbiol Mol Biol Rev* **66**, 671–701.

Ibanga, H. B., Brookes, R. H., Hill, P. C., Owiafe, P. K., Fletcher, H. A., Lienhardt, C., Hill, A. V., Adegbola, R. A. & McShane, H. (2006). Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. *Lancet Infect Dis* **6**, 522–528.

Mahairas, G. G., Sabo, P. J., Hickey, M. J., Singh, D. C. & Stover, C. K. (1996). Molecular analysis of genetic differences between *Mycobacterium bovis* BCG and virulent *M. bovis*. *J Bacteriol* **178**, 1274–1282.

Muttucumaru, D. G., Roberts, G., Hinds, J., Stabler, R. A. & Parish, T. (2004). Gene expression profile of *Mycobacterium tuberculosis* in a non-replicating state. *Tuberculosis (Edinb)* **84**, 239–246.

Orme, I. M. (2006). Preclinical testing of new vaccines for tuberculosis: a comprehensive review. *Vaccine* **24**, 2–19.

Pethe, K., Alonso, S., Biet, F., Delogu, G., Brennan, M. J., Locht, C. & Menozzi, F. D. (2001). The heparin-binding haemagglutinin of *M. tuberculosis* is required for extrapulmonary dissemination. *Nature* **412**, 190–194.

Pethe, K., Bifani, P., Drobecq, H., Sergheraert, C., Debrie, A. S., Locht, C. & Menozzi, F. D. (2002). Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyl-lysines that confer resistance to proteolysis. *Proc Natl Acad Sci U S A* **99**, 10759–10764.

Rao, V., Gao, F., Chen, B., Jacobs, W. R., Jr & Glickman, M. S. (2006). Trans-cyclopropanation of mycolic acids on trehalose dimycolate suppresses *Mycobacterium tuberculosis*-induced inflammation and virulence. *J Clin Invest* **116**, 1660–1667.

Sassetti, C. M. & Rubin, E. J. (2003). Genetic requirements for mycobacterial survival during infection. *Proc Natl Acad Sci U S A* **100**, 12989–12994.

Skjøt, R. L., Oettinger, T., Rosenkrands, I., Ravn, P., Brock, I., Jacobsen, S. & Andersen, P. (2000). Comparative evaluation of low-molecular-mass proteins from *Mycobacterium tuberculosis* identifies members of the ESAT-6 family as immunodominant T-cell antigens. *Infect Immun* **68**, 214–220.

Sørensen, A. L., Nagai, S., Houen, G., Andersen, P. & Andersen, A. B. (1995). Purification and characterization of a low-molecular-mass T-cell antigen secreted by *Mycobacterium tuberculosis*. *Infect Immun* **63**, 1710–1717.

Stinear, T. P., Seemann, T., Pidot, S., Frigui, W., Reysset, G., Garnier, T., Meurice, G., Simon, D., Bouchier, C. & other authors (2007). Reductive evolution and niche adaptation inferred from the genome of *Mycobacterium ulcerans*, the causative agent of Buruli ulcer. *Genome Res* **17**, 192–200.

Temmerman, S., Pethe, K., Parra, M., Alonso, S., Rouanet, C., Pickett, T., Drowart, A., Debrie, A. S., Delogu, G. & other authors (2004). Methylation-dependent T cell immunity to *Mycobacterium tuberculosis* heparin-binding hemagglutinin. *Nat Med* **10**, 935–941.

Vordermeier, H. M., Chambers, M. A., Buddle, B. M., Pollock, J. M. & Hewinson, R. G. (2006). Progress in the development of vaccines and diagnostic reagents to control. tuberculosis in cattle. *Vet J* **171**, 229–244.

Voskuil, M. I., Visconti, K. C. & Schoolnik, G. K. (2004). *Mycobacterium tuberculosis* gene expression during adaptation to stationary phase and low-oxygen dormancy. *Tuberculosis (Edinb)* **84**, 218–227.

Edited by: G. R. Stewart